Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma

Veethika Pandey, Peter Storz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The dismally slow improvement in patient survival over the years for pancreatic cancer patients is mainly due to two factors: the late diagnosis, at which point the disease is spread to distant organs; and the fact that tumor cells are surrounded by a dense, highly immunosuppressive microenvironment. The tumor microenvironment not only shields pancreatic cancer cells from chemotherapy but also leaves it unsusceptible to various immunotherapeutic strategies that have been proven successful in other types of cancer. Areas covered: This review highlights the main components of the pancreatic tumor microenvironment, how they cross-talk with each other to generate stroma and promote tumor growth. Additionally, we discuss the most promising treatment targets in the microenvironment whose modulation can be robustly tested in combination with standard of care chemotherapy. Currently, active clinical trials for pancreatic cancer involving components of the microenvironment are also listed. Expert opinion: Although immunotherapeutic approaches involving checkpoint inhibition are being pursued enthusiastically, there is still more work to be done with several other emerging immune targets that could provide therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)473-482
Number of pages10
JournalExpert review of anticancer therapy
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Tumor Microenvironment
Pancreatic Neoplasms
Adenocarcinoma
Drug Therapy
Neoplasms
Delayed Diagnosis
Expert Testimony
Standard of Care
Immunosuppressive Agents
Clinical Trials
Survival
Therapeutics
Growth

Keywords

  • fibroblasts
  • myeloid derived suppressor cells
  • Pancreatic cancer
  • stellate cells
  • tumor microenvironment
  • tumor-associated macrophages

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. / Pandey, Veethika; Storz, Peter.

In: Expert review of anticancer therapy, Vol. 19, No. 6, 01.06.2019, p. 473-482.

Research output: Contribution to journalArticle

@article{4bd05224fe5d4f84851ad5dcd0d81392,
title = "Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma",
abstract = "Introduction: The dismally slow improvement in patient survival over the years for pancreatic cancer patients is mainly due to two factors: the late diagnosis, at which point the disease is spread to distant organs; and the fact that tumor cells are surrounded by a dense, highly immunosuppressive microenvironment. The tumor microenvironment not only shields pancreatic cancer cells from chemotherapy but also leaves it unsusceptible to various immunotherapeutic strategies that have been proven successful in other types of cancer. Areas covered: This review highlights the main components of the pancreatic tumor microenvironment, how they cross-talk with each other to generate stroma and promote tumor growth. Additionally, we discuss the most promising treatment targets in the microenvironment whose modulation can be robustly tested in combination with standard of care chemotherapy. Currently, active clinical trials for pancreatic cancer involving components of the microenvironment are also listed. Expert opinion: Although immunotherapeutic approaches involving checkpoint inhibition are being pursued enthusiastically, there is still more work to be done with several other emerging immune targets that could provide therapeutic benefit.",
keywords = "fibroblasts, myeloid derived suppressor cells, Pancreatic cancer, stellate cells, tumor microenvironment, tumor-associated macrophages",
author = "Veethika Pandey and Peter Storz",
year = "2019",
month = "6",
day = "1",
doi = "10.1080/14737140.2019.1622417",
language = "English (US)",
volume = "19",
pages = "473--482",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma

AU - Pandey, Veethika

AU - Storz, Peter

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: The dismally slow improvement in patient survival over the years for pancreatic cancer patients is mainly due to two factors: the late diagnosis, at which point the disease is spread to distant organs; and the fact that tumor cells are surrounded by a dense, highly immunosuppressive microenvironment. The tumor microenvironment not only shields pancreatic cancer cells from chemotherapy but also leaves it unsusceptible to various immunotherapeutic strategies that have been proven successful in other types of cancer. Areas covered: This review highlights the main components of the pancreatic tumor microenvironment, how they cross-talk with each other to generate stroma and promote tumor growth. Additionally, we discuss the most promising treatment targets in the microenvironment whose modulation can be robustly tested in combination with standard of care chemotherapy. Currently, active clinical trials for pancreatic cancer involving components of the microenvironment are also listed. Expert opinion: Although immunotherapeutic approaches involving checkpoint inhibition are being pursued enthusiastically, there is still more work to be done with several other emerging immune targets that could provide therapeutic benefit.

AB - Introduction: The dismally slow improvement in patient survival over the years for pancreatic cancer patients is mainly due to two factors: the late diagnosis, at which point the disease is spread to distant organs; and the fact that tumor cells are surrounded by a dense, highly immunosuppressive microenvironment. The tumor microenvironment not only shields pancreatic cancer cells from chemotherapy but also leaves it unsusceptible to various immunotherapeutic strategies that have been proven successful in other types of cancer. Areas covered: This review highlights the main components of the pancreatic tumor microenvironment, how they cross-talk with each other to generate stroma and promote tumor growth. Additionally, we discuss the most promising treatment targets in the microenvironment whose modulation can be robustly tested in combination with standard of care chemotherapy. Currently, active clinical trials for pancreatic cancer involving components of the microenvironment are also listed. Expert opinion: Although immunotherapeutic approaches involving checkpoint inhibition are being pursued enthusiastically, there is still more work to be done with several other emerging immune targets that could provide therapeutic benefit.

KW - fibroblasts

KW - myeloid derived suppressor cells

KW - Pancreatic cancer

KW - stellate cells

KW - tumor microenvironment

KW - tumor-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85067177860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067177860&partnerID=8YFLogxK

U2 - 10.1080/14737140.2019.1622417

DO - 10.1080/14737140.2019.1622417

M3 - Article

VL - 19

SP - 473

EP - 482

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -